AngioDynamics (NASDAQ:ANGO) Upgraded to B by TheStreet Posted by Scott Davis on Jul 14th, 2019
TheStreet upgraded shares of AngioDynamics (NASDAQ:ANGO) from a c rating to a b rating in a research note released on Wednesday morning, TheStreetRatingsTable reports.
Other analysts also recently issued reports about the company. ValuEngine downgraded Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Zacks Investment Research upgraded Investar from a hold rating to a buy rating and set a $27.00 price objective for the company in a report on Tuesday, June 4th. Finally, BidaskClub upgraded Westport Fuel Systems from a hold rating to a buy rating in a report on Friday. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $21.50. Get AngioDynamics alerts:
Shares of NASDAQ:ANGO opened at $21.68 on Wednesday. The business’s fifty day moving average is $19.62. The firm has a market capitalization of $814.66 million, a P/E ratio of 26.12 and a beta of 0.69. The company has a quick ratio of 1.70, a current ratio of 4.30 and a debt-to-equity ratio of 0.20. AngioDynamics has a 52-week low of $18.11 and a 52-week high of $25.48. AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.26 by ($0.01). The company had revenue of $96.30 million during the quarter, compared to analyst estimates of $92.34 million. AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.20 earnings per share. Sell-side analysts expect that AngioDynamics will post 0.27 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Penn Capital Management Co. Inc. acquired a new stake in AngioDynamics in the fourth quarter valued at $2,057,000. Metropolitan Life Insurance Co. NY boosted its position in AngioDynamics by 417.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,559 shares of the medical instruments supplier’s stock valued at $253,000 after acquiring an additional 10,130 shares during the last quarter. South Dakota Investment Council boosted its position in AngioDynamics by 53.4% during the first quarter. South Dakota Investment Council now owns 15,800 shares of the medical instruments supplier’s stock valued at $361,000 after acquiring an additional 5,500 shares during the last quarter. Tibra Equities Europe Ltd bought a new stake in AngioDynamics during the first quarter valued at $245,000. Finally, Segall Bryant & Hamill LLC boosted its position in AngioDynamics by 19.2% during the fourth quarter. Segall Bryant & Hamill LLC now owns 1,136,657 shares of the medical instruments supplier’s stock valued at $22,881,000 after acquiring an additional 183,368 shares during the last quarter. Institutional investors and hedge funds own 98.46% of the company’s stock.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.